Clinical trial
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal…
NCT03056040 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT03056040 |
|---|---|
| Title | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab |
| Official title | A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Intervention type | Biological |
| Interventions | Ravulizumab, Eculizumab |
| Enrollment | 202 |
| Start date | May 17, 2017 |
| Primary completion | Feb 21, 2022 |
| Completion | Feb 21, 2022 |
| First posted | Feb 16, 2017 |
| Last update posted | Mar 12, 2025 |
| Countries | Australia, Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: